We are advancing a diverse pipeline of immune modulators, including orally-active small moledules and monoclonal antibodies, to address major unmet needs in autoimmune diseases and allergic inflammation. We plan to begin enrollment of patients in our Phase 2 studies in ulcerative colitis (UC) and Crohn's disease (CD) for CBP-307 and initiate our first-in-man studies of CBP-201 in 2018.



TEL/FAX: 0512-53577866

E-MAIL: qchang@connectpharm.com

ADD: Science and Technology Park, East R&D Building , 3rd Floor , 6 Beijing West Road, Taichang, Jiangsu, China 215400

Copyright: Suzhou Connect Biopharmaceuticals, Ltd.

Technical support: Epower